These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 25192975)

  • 61. Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China.
    Wang W; Wang H; Deng Y; Song T; Lan J; Wu G; Ke C; Tan W
    Emerg Microbes Infect; 2016 Nov; 5(11):e113. PubMed ID: 27826140
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013.
    Meyer B; Müller MA; Corman VM; Reusken CB; Ritz D; Godeke GJ; Lattwein E; Kallies S; Siemens A; van Beek J; Drexler JF; Muth D; Bosch BJ; Wernery U; Koopmans MP; Wernery R; Drosten C
    Emerg Infect Dis; 2014 Apr; 20(4):552-9. PubMed ID: 24655412
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus.
    Lan J; Deng Y; Song J; Huang B; Wang W; Tan W
    Virol Sin; 2018 Oct; 33(5):453-455. PubMed ID: 30374826
    [No Abstract]   [Full Text] [Related]  

  • 64. Development and characterization of three novel mouse monoclonal antibodies targeting spike protein S1 subunit of Middle East respiratory syndrome corona virus.
    Abbas AT; El-Kafrawy SA; Tabll AA; Hashem AM; Al Subhi TL; Alsaadi M; Azhar EI
    Hum Antibodies; 2024; 32(3):129-137. PubMed ID: 38758996
    [TBL] [Abstract][Full Text] [Related]  

  • 65. MERS-CoV spike protein: Targets for vaccines and therapeutics.
    Wang Q; Wong G; Lu G; Yan J; Gao GF
    Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors.
    Widagdo W; Okba NMA; Li W; de Jong A; de Swart RL; Begeman L; van den Brand JMA; Bosch BJ; Haagmans BL
    J Virol; 2019 Aug; 93(16):. PubMed ID: 31167913
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.
    Excler JL; Delvecchio CJ; Wiley RE; Williams M; Yoon IK; Modjarrad K; Boujelal M; Moorthy VS; Hersi AS; Kim JH;
    Emerg Infect Dis; 2016 Aug; 22(8):. PubMed ID: 27439020
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular aspects of MERS-CoV.
    Rabaan AA; Bazzi AM; Al-Ahmed SH; Al-Tawfiq JA
    Front Med; 2017 Sep; 11(3):365-377. PubMed ID: 28500431
    [TBL] [Abstract][Full Text] [Related]  

  • 69. High Rate of Circulating MERS-CoV in Dromedary Camels at Slaughterhouses in Riyadh, 2019.
    Aljasim TA; Almasoud A; Aljami HA; Alenazi MW; Alsagaby SA; Alsaleh AN; Alharbi NK
    Viruses; 2020 Oct; 12(11):. PubMed ID: 33120981
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization.
    Liu R; Wang J; Shao Y; Wang X; Zhang H; Shuai L; Ge J; Wen Z; Bu Z
    Antiviral Res; 2018 Feb; 150():30-38. PubMed ID: 29246504
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
    Tang XC; Agnihothram SS; Jiao Y; Stanhope J; Graham RL; Peterson EC; Avnir Y; Tallarico AS; Sheehan J; Zhu Q; Baric RS; Marasco WA
    Proc Natl Acad Sci U S A; 2014 May; 111(19):E2018-26. PubMed ID: 24778221
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA.
    Fukushi S; Fukuma A; Kurosu T; Watanabe S; Shimojima M; Shirato K; Iwata-Yoshikawa N; Nagata N; Ohnishi K; Ato M; Melaku SK; Sentsui H; Saijo M
    J Virol Methods; 2018 Jan; 251():22-29. PubMed ID: 28993122
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice.
    Veit S; Jany S; Fux R; Sutter G; Volz A
    Viruses; 2018 Dec; 10(12):. PubMed ID: 30558354
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016.
    Ali M; El-Shesheny R; Kandeil A; Shehata M; Elsokary B; Gomaa M; Hassan N; El Sayed A; El-Taweel A; Sobhy H; Fasina FO; Dauphin G; El Masry I; Wolde AW; Daszak P; Miller M; VonDobschuetz S; Morzaria S; Lubroth J; Makonnen YJ
    Euro Surveill; 2017 Mar; 22(11):. PubMed ID: 28333616
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MERS-CoV‒Specific T-Cell Responses in Camels after Single MVA-MERS-S Vaccination.
    Meyer Zu Natrup C; Schünemann LM; Saletti G; Clever S; Herder V; Joseph S; Rodriguez M; Wernery U; Sutter G; Volz A
    Emerg Infect Dis; 2023 Jun; 29(6):1236-1239. PubMed ID: 37209676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen.
    Pallesen J; Wang N; Corbett KS; Wrapp D; Kirchdoerfer RN; Turner HL; Cottrell CA; Becker MM; Wang L; Shi W; Kong WP; Andres EL; Kettenbach AN; Denison MR; Chappell JD; Graham BS; Ward AB; McLellan JS
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7348-E7357. PubMed ID: 28807998
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
    Tai W; Zhao G; Sun S; Guo Y; Wang Y; Tao X; Tseng CK; Li F; Jiang S; Du L; Zhou Y
    Virology; 2016 Dec; 499():375-382. PubMed ID: 27750111
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vaccines against Middle East respiratory syndrome coronavirus for humans and camels.
    Alharbi NK
    Rev Med Virol; 2017 Mar; 27(2):. PubMed ID: 27786402
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A longitudinal study of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels.
    Abdelazim M; Abdelkader R; Ali A; Shahein MA; Tadesse Z; Saad A; Mansour A; Ali SF; Atea M; Gardner E; VonDobschuetz S; Morzaria S; Makonnen Y; Lubroth J; Sumption K; ElMasry I; Zakaria T; Eid S; Hatab EA; Hagag NM; Yousef HMY; Emara M; Abdelwahed DA; Abdelmegeed HK; Hamdy ME; Mansour ONO; Guitian J
    BMC Vet Res; 2023 Nov; 19(1):228. PubMed ID: 37919680
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels.
    Zhang W; Zheng XS; Agwanda B; Ommeh S; Zhao K; Lichoti J; Wang N; Chen J; Li B; Yang XL; Mani S; Ngeiywa KJ; Zhu Y; Hu B; Onyuok SO; Yan B; Anderson DE; Wang LF; Zhou P; Shi ZL
    Emerg Microbes Infect; 2019; 8(1):1528-1534. PubMed ID: 31645223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.